Dose escalation trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid haemorrhage
Masatoshi Shibuya(Tohoku University), Hisashi Hidaka(Kitasato University), Yasuhíro Suzuki(Osaka City University), Shinichiro Okamoto(Kyoto University), Takaaki Sasaki(Asahikawa Medical College Hospital), I. Saito(Nagoya University), Kintomo Takakura(Nagoya University), Koshiro Sugita(Nagoya University), Toshiki Takemae(Shinshu University), H. Kikuchi(Kyoto University)
Cited by 33
Related Papers
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k
KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II.
|Journal of Biological Chemistry|1990|625
N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation.
|Proceedings of the National Academy of Sciences|1981|586
Selective inhibition of catalytic activity of smooth muscle myosin light chain kinase.
|Journal of Biological Chemistry|1987|513
MAPKAP kinase‐2; a novel protein kinase activated by mitogen‐activated protein kinase.
|The EMBO Journal|1992|481